跳转至内容
Merck

R9644

Sigma-Aldrich

利巴韦林

antiviral

别名:

1-β-D-呋喃核糖基-1,2,4-三唑-3-甲酰胺

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C8H12N4O5
CAS号:
分子量:
244.20
MDL號碼:
分類程式碼代碼:
12352202
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥98% (TLC)

形狀

powder

溶解度

water: 19.60-20.40 mg/mL, clear, colorless to faintly yellow

抗生素活性譜

viruses

作用方式

DNA synthesis | interferes

儲存溫度

2-8°C

SMILES 字串

NC(=O)c1ncn(n1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O

InChI

1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1

InChI 密鑰

IWUCXVSUMQZMFG-AFCXAGJDSA-N

基因資訊

正在寻找类似产品? 访问 产品对比指南

一般說明

化学结构:核苷
嘌呤核苷酸生物合成中咪唑核苷酸中间体的类似物。

生化/生理作用

抗病毒剂。其代谢产物利巴韦林 5′-磷酸,是肌苷一磷酸 (IMP) 脱氢酶的抑制剂。用于抑制嘌呤(GTP 池)在肌苷单磷酸 (IMP) 脱氢酶级别的生物合成,并作为抑制病毒RNA依赖性RNA聚合酶的二磷酸和三磷酸的前体。
用于抵御多种人类病毒感染的抗病毒剂,特别是慢性肝炎C、HIV 和腺病毒。其代谢产物利巴韦林 5′-磷酸,是肌苷一磷酸 (IMP) 脱氢酶的抑制剂。
用于抵御多种人类病毒感染的抗病毒剂,特别是慢性肝炎C、HIV 和腺病毒。其代谢产物利巴韦林 5′-磷酸,是肌苷一磷酸 (IMP) 脱氢酶的抑制剂,但也有实验证据支持许多其他作用机制。

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Muta. 2 - Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Rahma F Hayati et al.
BioMed research international, 2021, 6623400-6623400 (2021-04-16)
Chikungunya (CHIK) is a reemerging arboviral disease caused by chikungunya virus (CHIKV) infection. The disease is clinically hallmarked by prolonged debilitating joint pain. Currently, there is no specific antiviral medication nor commercial vaccine available for treatment of the disease, which
Fred Poordad et al.
The New England journal of medicine, 370(21), 1973-1982 (2014-04-15)
Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir
Michael Manns et al.
Lancet (London, England), 384(9954), 1597-1605 (2014-08-01)
An unmet need exists for interferon-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection. In this study, we assessed all-oral therapy with daclatasvir (NS5A replication complex inhibitor) plus asunaprevir (NS3 protease inhibitor) in patients with genotype 1b infection
W Markland et al.
Antimicrobial agents and chemotherapy, 44(4), 859-866 (2000-03-18)
The enzyme IMP dehydrogenase (IMPDH) catalyzes an essential step in the de novo biosynthesis of guanine nucleotides, namely, the conversion of IMP to XMP. The major event occurring in cells exposed to competitive IMPDH inhibitors such as ribavirin or uncompetitive
Chen-Hua Liu et al.
Annals of internal medicine, 159(11), 729-738 (2013-12-04)
Data are limited on the efficacy and safety of pegylated interferon plus ribavirin for patients with hepatitis C virus genotype 1 (HCV-1) receiving hemodialysis. To compare the efficacy and safety of combination therapy with pegylated interferon plus low-dose ribavirin and

商品

Neoplastic cells are highly dependent on the de novo synthesis of nucleotides to maintain sufficient pools to support DNA replication and the production of RNA.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门